Vertex Pharmaceuticals Inc (VRTX)vsYD Bio Ltd (YDES)
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
YDES
YD Bio Ltd
$7.73
+19.11%
HEALTHCARE · Cap: $457.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2351436% more annual revenue ($12.00B vs $510,360). VRTX leads profitability with a 32.9% profit margin vs -2.8%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
VRTX
Strong Buy66
out of 100
Grade: B-
YDES
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Intrinsic value data unavailable for YDES.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Revenue surging 95.6% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -42.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bull Case : YDES
The strongest argument for YDES centers on Revenue Growth, Price/Book. Revenue growth of 95.6% demonstrates continued momentum.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : YDES
The primary concerns for YDES are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
VRTX profiles as a mature stock while YDES is a hypergrowth play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.32 — expect wider price swings.
YDES is growing revenue faster at 95.6% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 22/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
YD Bio Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?